Whole genome sequencing-powered ctDNA sequencing for breast cancer detection
A whole genome-powered MRD assay detected breast cancer relapse with a long lead time over clinical relapse, and was strongly associated with relapse-free survival. Rates of ctDNA detection at diagnosis were higher than those reported with exome-based tumour-informed assays.
Authors
- AA Evans
- Charles W. Abbott (ORCID: https://orcid.org/0000-0002-3837-6471)
- Kevin Dunne (ORCID: https://orcid.org/0009-0003-0393-8037)
- S. Johnston
- Isaac García-Murillas (ORCID: https://orcid.org/0000-0001-8183-7969)
- Jacqueline A. Pugh (ORCID: https://orcid.org/0000-0003-4933-141X)
- Alexander Ring (ORCID: https://orcid.org/0000-0002-0092-1323)
- Fábio C. P. Navarro (ORCID: https://orcid.org/0000-0002-5640-9070)
- Rosalind Cutts (ORCID: https://orcid.org/0000-0002-8297-9341)
- Simon Russell (ORCID: https://orcid.org/0000-0001-9447-1169)
- Richard Chen (ORCID: https://orcid.org/0000-0002-2842-4476)
- Catey Bunce (ORCID: https://orcid.org/0000-0002-0935-3713)
- N.C. Turner
- S.M. Boyle
- R M Pyke
- Kathleen C. Keough (ORCID: https://orcid.org/0000-0002-7481-0511)
- Bo Li (ORCID: https://orcid.org/0000-0001-9944-0003)
- A. Skene
- I. E. Smith
Institutions
- Institute of Cancer Research (GB)
- Breast Cancer Now (GB)
- Royal Bournemouth Hospital (GB)
- Poole Hospital (GB)
- Hinchingbrooke Hospital (GB)
- Personalis (United States) (US)
- Royal Marsden Hospital (GB)
Publication Details
- Journal
- Annals of Oncology
- Published
- 2025-02-04
- DOI
- https://doi.org/10.1016/j.annonc.2025.01.021
- Citations
- 30
- Primary Topic
- Cancer Genomics and Diagnostics
- Type
- article
- Field-Weighted Citation Impact
- 28.09
Funders
- Breast Cancer Now
- Royal Marsden Cancer Charity
- National Institute for Health and Care Research